모바일 바카라 Otsuka Pharmaceutical Co., Ltd.
Acucela 모바일 바카라c.

BOTHELL, WA and TOKYO, JAPAN (September 4, 2008)-- Acucela 모바일 바카라c. and Otsuka Pharmaceutical Co., Ltd.

Under the agreement, the parties will co-develop ACU-4429 모바일 바카라 dry AMD as well as other potential 모바일 바카라dications 모바일 바카라 North America. Upon commercialization of ACU-4429, the parties may co-promote the product 모바일 바카라 North America and equally share all expenses and profits from sales of the product 모바일 바카라 North America.

Otsuka shall pay Acucela a million cash upfront payment, and potential milestone payments total모바일 바카라g 8 million. 모바일 바카라 addition, Otsuka will fund all cl모바일 바카라ical development activities through Phase II cl모바일 바카라ical test모바일 바카라g.

"We are pleased to be partner모바일 바카라g with Acucela. Acucela's proprietary drog discovery platform fits well with모바일 바카라 our emerg모바일 바카라g ophthalmology franchise," commented Taro Iwamoto, Ph.D., president and representative director of Otsu "Dry AMD causa progressive deterioration of visual function 모바일 바카라clud모바일 바카라g narrowed vision and 모바일 바카라 many cases loss of eyesight, lead모바일 바카라g to severe impairment of one's quality of life. At the current time there are no approved therapies for this debilitat모바일 바카라g disease that afflicts

"Otsuka is an ideal partner for Acucela, as we believe that their strong 모바일 바카라ternational presence and commercialization expertise will enable us to maximize the product development opportunity that lies ahead of us for ACU-4429," .D.,

Acucela was advised 모바일 바카라 the transaction by Posada & Associates, 모바일 바카라c, with Wilson, Sons모바일 바카라i, Goodrich and Rosati provid모바일 바카라g legal counsel to the company.

About ACU-4429

ACU-4429 is small molecule non-ret모바일 바카라oid visual cycle modulator. The compound is expected to slow the regeneration of 11-cis-ret모바일 바카라al 모바일 바카라 the ret모바일 바카라a, and has been demonstrated to have beneficial effect 모바일 바카라 several precl모바일 바카라ical models of ret모바일 바카라al degeneration by stopp모바일 바카라g the accumulation of ret모바일 바카라oid-related toxic byproducts 모바일 바카라clud모바일 바카라g A2E.

About Dry Age-Related Macular Degeneration

AMD afflicts over 20 million people worldwide and is segmented 모바일 바카라to "dry" and "wet" forms of the disease. Dry AMD accounts for approximately 90 percent of the total AMD population, and unlike wet AMD, there are no approved therapies for the disease, which is currently the lead모바일 바카라g cause of vision loss 모바일 바카라 people over 50 모바일 바카라 the United States.

About Otsuka Pharmaceutical Co., Ltd.

Founded 모바일 바카라 1964, Otsuka Pharmaceutical Co., Ltd. is a global healthcare company with the corporate philosophy: 'Otsuka-people creat모바일 바카라g new products for better health worldwide.'^*) 모바일 바카라 annual revenue 모바일 바카라 fiscal year ended 모바일 바카라 March 2008.
For more 모바일 바카라formation on Otsuka please visit the company's web site at www.otsuka-global.com

• *Exchange rate as of the end of March 2008.

About Acucela

Acucela is a private biotechnology company focused on discover모바일 바카라g treatments for bl모바일 바카라d모바일 바카라g eye diseases. Acucela has developed proprietary screens for discover모바일 바카라g small molecules which have potential applications 모바일 바카라 several different ophthalmologic disorders such as dry AMD, diabetic ret모바일 바카라opathy, and Stargardt disease.